PRESIDENT HAS SERVED AS A REVIEWER FOR THE ZRG1 BST-H (50) PAR-16-390 ‘NIBIB Trailblazer Award for New and Early Stage Investigators’ (R21) STUDY SECTION FOR THE NIH
PDX Pharma’s President has served as a reviewer for the ZRG1 BST-H (50) PAR-16-390 ‘NIBIB Trailblazer Award for New and Early Stage Investigators’ (R21) Study Section for the National Institute of Health (NIH) held on June 28, 2017.
pdx news
PDX pharma awarded SBIR grant from the National Cancer Institute (total of $2.4M) for the development of PETTRA, a novel lung cancer treatment
PDX Pharma awarded two-year $1.87M phase II SBIR grant from the National Cancer Institute (NCI) for the development of ARAC-02, a novel lung cancer treatment